Recurrent primary biliary cirrhosis peritransplant factors and ursodeoxycholic acid treatment post-liver transplant

Liver Transplantation

Volumn 11, Issue 10, 2005, Pages 1252-1257

  Guy, Jennifer E ^a   Qian, Peiqing ^b   Lowell, Jeffrey A ^b   Peters, Marion G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYCLOSPORIN; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOMEGALOVIRUS; DISEASE EXACERBATION; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; ORGAN DONOR; PERIOPERATIVE PERIOD; PILOT STUDY; POSTOPERATIVE CARE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RECIPIENT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 27244448261     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20511     Document Type: Article

References (42)

1. Saksena S, Tandon RK. Ursodeoxycholic acid in the treatment of liver diseases. Postgrad Med J 1997;73:75-80.
2. Setchell KD, Rodrigues CM, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997; 112:226-235.
3. Guldutuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993;104:1736-1744.
4. Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992;103:617-621.
5. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004;8:67-81, vi.
6. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-1060.
7. Combes B, Luketic VA, Peters MG, Zetterman R, Garcia Tsao G, Munoz SJ. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004;99:264-268.
8. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-1156.
9. Lindor KD, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000;355:657-658.
10. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324: 1548-1554.
11. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-1347.
12. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
13. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-1199.
14. Pares A, Caballeria L, Rodes J, Bruguaera M, Rodrigo L, Garcia-Plaza A, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-566.
15. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16.
16. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29: 644-647.
17. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122: 652-658.
18. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33:22-27.
19. Tinmouth J, Tomlinson G, Heathcote EJ, Lilly L. Benefit of transplantation in primary biliary cirrhosis between 1985-1997. Transplantation 2002;73:224-227.
20. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2003;9:539-546.
21. Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982;306:1-4.
22. Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 2003;9:87-96.
23. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 2003;9:1086-1093.
24. Hubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18:173-184.
25. Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J, French-PBC Study Group. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004;40:489-494.
26. Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29:21-26.
27. Locke GR 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52-56.
28. Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chretren Y, Poupon RE, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 2004;24:187-193.
29. Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997;25:6-11.
30. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
31. Peters M. Pathogenesis of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangiopathy. Clin Liver Dis 1998;2:235-247.
32. Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, Gershwin ME. Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 1994;43:71-77.
33. Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER. Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology 1987;7:889-892.
34. Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991;101:1367-1373.
35. Morling N, Dalhoff K, Fugger L, Georgsen J, Jakobsen B, Ranek L, et al. DNA polymorphism of HLA class II genes in primary biliary cirrhosis. Immunogenetics 1992;35:112-116.
36. Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992;16:1404-1408.
37. Gregory WL, Mehal W, Dunn AN, Cavanagh G, Chapman R, Fleming KA, et al. Primary biliary cirrhosis: contribution of HLA class II allele DR8. Q J Med 1993;86:393-399.
38. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10:488-491.
39. Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, Netto GJ, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003;76:1583-1588.
40. Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003;9:733-736.
41. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
42. McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004;10:975-985.